3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
11
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
246
Precursor Cell Lymphoblastic Leukemia-Lymphoma
147
Myelodysplastic Syndromes
141
Leukemia, Lymphocytic, Chronic, B-Cell
140
Leukemia
128
Lymphoma
80
Hematologic Neoplasms
77
Lymphoma, Non-Hodgkin
73
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Hodgkin Disease
55
Multiple Myeloma
54
Myeloproliferative Disorders
37
Recurrence
34
Lymphoma, Mantle-Cell
29
Graft vs Host Disease
28
Burkitt Lymphoma
28
Lymphoma, B-Cell
26
Lymphoma, Follicular
25
Leukemia, Biphenotypic, Acute
25
Anemia, Refractory, with Excess of Blasts
23
Leukemia, Myelomonocytic, Chronic
22
Lymphoma, Large B-Cell, Diffuse
21
Neoplasms, Plasma Cell
20
Lymphoma, B-Cell, Marginal Zone
20
Primary Myelofibrosis
19
Leukemia, Prolymphocytic
14
Leukemia, Myeloid
13
Anemia, Aplastic
13
Neoplasms
12
Leukemia, Myelomonocytic, Juvenile
11
Interventions
Paclitaxel
2
Azacitidine
2
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pembrolizumab
1
fludarabine
1
ceritinib
1
cc-486
1
carboxyamido-triazole
1
bemcentinib
1
acalabrutinib
1
abiraterone
1
Uncertainty
1
Thalidomide
1
Temozolomide
1
Sorafenib
1
Quality of Life
1
Psychosocial Intervention
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
O(6)-benzylguanine
1
Molecular Diagnostic Techniques
1
Leucovorin
1
Lenalidomide
1
Interleukin-2
1
Interleukin-15
1
Injections
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
fludarabine
×
Other hematologic neoplasm
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled